Frontiers | Monoclonal Antibodies and Immune Checkpoint Inhibitors in the treatment of Cancer

Monoclonal Antibodies and Immune Checkpoint Inhibitors in the treatment of Cancer

25k
Total downloads
77k
Total views and downloads

Download PDF Download EPUB

Articles

ORIGINAL RESEARCH

Published on 29 Oct 2024

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

Toshio Shimizu
John Powderly
Albiruni Abdul Razak
Patricia LoRusso
Kathy D. Miller
Steven Kao
Sarah Kongpachith
Catherine Tribouley
Michelle Graham
6 more
Anthony Tolcher

doi 10.3389/fonc.2024.1376551

1,495 views

REVIEW

Published on 30 Sep 2024

Prognostic biomarkers for immunotherapy in esophageal cancer

Xu Tong
Meiyuan Jin
Lulu Wang
Dongli Zhang
Yuping Yin
Qian Shen

doi 10.3389/fimmu.2024.1420399

1,207 views

ORIGINAL RESEARCH

Published on 15 Jul 2024

Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells

Yunlong He
Depeng Yang
Xiaoyu Lin
Jinfeng Zhang
Rui Cheng
Liangyu Cao
Lijun Yang
Mengmeng Zhang
Xinyue Shi
6 more
Huan Nie

doi 10.3389/fimmu.2024.1412693

1,173 views

ORIGINAL RESEARCH

Published on 26 Jun 2024

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Cecilia Olsson Ladjevardi
Anthoula Koliadi
Viktoria Rydén
Ali Inan El-Naggar
Evangelos Digkas
Antonios Valachis
Gustav J. Ullenhag

doi 10.3389/fonc.2024.1399171

917 views
1 citation

CASE REPORT

Published on 24 May 2024

Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC

Liqianqi Chen
Suihao Zhang
Long Gong
Yucong Zhang

doi 10.3389/fonc.2024.1404045

650 views
1 citation

SYSTEMATIC REVIEW

Published on 17 May 2024

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis

Xin Shen
Jun Yang
Geng Qian
Mingyu Sheng
Yu Wang
Guohui Li
Jiaqing Yan

doi 10.3389/fonc.2024.1391724

802 views
3 citations

ORIGINAL RESEARCH

Published on 12 Apr 2024

Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma

Wendy W. L. Lee
Jing Quan Lim
Tiffany P. L. Tang
Daryl Tan
Ser Mei Koh
Kia Joo Puan
Liang Wei Wang
Jackwee Lim
Kim Peng Tan
3 more
Olaf Rotzschke

doi 10.3389/fimmu.2024.1346178

2,370 views

SYSTEMATIC REVIEW

Published on 05 Apr 2024

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

Wenjing Zhang
Zhanpeng Liang
Yurong Zhao
Yanwei Li
Ting Chen
Wenxia Li
Yunqi Chen
Peiye Wu
Huatang Zhang
1 more
Luzhen Li

doi 10.3389/fimmu.2024.1359302

2,785 views
2 citations

CASE REPORT

Published on 29 Feb 2024

The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report

Wang Deng
Juan Chen
Xin-Yu Deng

doi 10.3389/fimmu.2024.1333850

1,244 views
1 citation

REVIEW

Published on 12 Feb 2024

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Ting Yan
Lun Yu
Jiwen Zhang
Yun Chen
Yilan Fu
Jingyi Tang
Dehua Liao

doi 10.3389/fimmu.2024.1292122

2,742 views
3 citations

ORIGINAL RESEARCH

Published on 25 Jan 2024

Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion

Ju-Li Lin
Mi Lin
Guang-Tan Lin
Qing Zhong
Jun Lu
Chao-Hui Zheng
Jian-Wei Xie
Jia-bin Wang
Chang-Ming Huang
Ping Li

doi 10.3389/fimmu.2024.1322152

768 views
3 citations

SYSTEMATIC REVIEW

Published on 24 Jan 2024

Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review

Yun-zi Wang
Ji-sheng Wang
Jiang Du
Xue-li Tang
Jing-ping Xiao

doi 10.3389/fimmu.2024.1305810

1,570 views
2 citations

Share on

Frontiers in Oncology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- 5.7 impact factor
- 9.8 citescore

Impact

77kTopic views
49kArticle views
25kArticle downloads

View impact

Submit your idea

Articles

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

Prognostic biomarkers for immunotherapy in esophageal cancer

Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis

Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion

Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review

Frontiers in Oncology

Participating Journals

Impact